Research programme: leukaemia stem cell therapeutics - Carna Biosciences
Latest Information Update: 08 Jul 2016
At a glance
- Originator Carna Biosciences
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Leukaemia
Most Recent Events
- 08 Jul 2016 Early research in Leukaemia in USA (unspecified route)